Investing in Health Care Reform

by Charles Rotblut, CFA

Investing In Health Care Reform Splash image

Like any piece of major legislation, the new health care reform law brings both opportunities and potential traps for investors.

To help AAII members identify both, we contacted a few companies that run health care sector mutual funds. Fidelity, Janus and T. Rowe Price either made their health care fund managers available for comment or provided copies of internal interviews with their respective managers on this topic. Table 1 shows the performance of the health care funds managed by those whose views we present.

A common theme, not surprisingly, was that the cloud of political uncertainty has been lifted from the health care sector. Going forward, mutual fund managers think the emphasis will be on cost controls and innovation. Health care companies that provide either, or both, stand most likely to benefit.

...To continue reading this article you must be registered with AAII.

Gain exclusive access to this article and all of the member benefits and investment education AAII offers.
JOIN TODAY for just $29.
Register for FREE
to read this article and receive access to future articles.

Log in
Already registered with AAII? Login to read the rest of this article.
Charles Rotblut, CFA is a vice president at AAII and editor of the AAII Journal. Follow him on Twitter at


David from Delaware posted over 3 years ago:

I have moral qualms about the idea that information technology will bring in high profits by reinventing the wheel many times. The VA, in fact, has an excellent IT program that is on its 9th (or more) revision which involves transferring images and data records nationwide among its medial centers. If public monies are being spent for such IT, why is it not in the public domain? Of course, communication links with other systems can be a stumbling block and require work.

The healthcare reform will boost a sector not mentioned specifically in the article. As drugs are tailored to a patient's genetic profile, either in the testing of new drugs or expended application of old drugs AND in identifying genetic profiles of future patients by practitioners, there is tremendous market for the makers of genetic tests and thelabs doing such testing. Developing such testing kits for simple application is also an area for growth. I'd like to see an article identifying such companies that would profit from not just an increased population of patients, but for this future development in medical practice. I believe ABT and LH are examples of companies profiting from such a development.

Maurice from California posted about 1 year ago:

The prospectus for Prudential Jennison Health Sciences Fund states: "For taxable years beginning after December 31, 2012, a U.S. shareholder.. will be subject to a 3.8% Medicare contribution tax on the lesser of (1) the shareholder's 'net investment income' including Fund distributions and net gains from the disposition of Fund shares, and (2) the excess of shareholder's modified adjusted gross income for the taxable year over a certain threshold."
Question: Is this 3.8% Medicare contribution tax applicable to all investments or only to Health related funds?

Bruce from Nevada posted about 1 year ago:

Maurice's question is a good one. As they say the devil is in the details. Anybody have the answer?

Bruce from Nevada posted about 1 year ago:

As usual I found the answer after I asked the question. Scroll to the top of this page and look at the right hand column. There are several discussion on taxes.

You need to log in as a registered AAII user before commenting.
Create an account

Log In